Depletion of chemoresponsive mitochondrial fission mediator DRP1 does not mitigate sarcoma resistance
Karolina Borankova, Matyas Solny, Mária Krchniaková, Jan Skoda
This study shows that reducing DRP1 activity in pediatric sarcomas does not improve drug sensitivity, suggesting DRP1 is not a key driver of chemoresistance in these cancers.
Life Science Alliance · Dec 6, 2024Peer-reviewedCancer Biology